Company news

BriaCell Therapeutics Corp news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

October 21, 2025

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

October 20, 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

October 13, 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

October 3, 2025

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

August 26, 2025

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

August 25, 2025

BriaCell Announces Proposed Effective Date of Share Consolidation

August 21, 2025

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

August 13, 2025

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

July 31, 2025

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

July 30, 2025

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

July 29, 2025

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

July 25, 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

July 16, 2025

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

July 15, 2025

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

July 15, 2025

BriaCell's Bria-IMT(TM) Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

July 11, 2025

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

July 11, 2025

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

July 10, 2025

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

July 9, 2025

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

July 8, 2025

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

July 2, 2025

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

June 24, 2025

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

June 4, 2025

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

June 2, 2025

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 27, 2025

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 23, 2025

BriaCell CEO Letter to Shareholders

May 20, 2025

BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

April 30, 2025

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

April 30, 2025

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

April 28, 2025

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

April 28, 2025

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

April 24, 2025

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

April 24, 2025

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

April 23, 2025

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

April 22, 2025

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

April 16, 2025

BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

April 10, 2025

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

March 26, 2025

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

March 20, 2025

BriaCell Virtually Opens the Market

February 10, 2022

NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Leveraging Combination Studies, Immune Checkpoint Inhibitors for Potent Anti-Cancer Response

October 4, 2018

BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

September 21, 2018

BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel

June 13, 2018

Research Reports Initiated on Healthcare Stocks Aphria, Antibe Therapeutics, BriaCell Therapeutics, and IntelGenx Technologies

March 7, 2017

Ansell Capital Corp announces additional drill results at Charlotte Property, Yukon

November 8, 2011

Ansell Capital Announces Joint Venture Partner Great Bear Commences Drilling At Etzel Gold Project, Yukon

September 19, 2011

Investment Industry Regulatory Organization of Canada - Trade Resumption - ANSELL CAPITAL CORP - ACP

September 6, 2011

Ansell capital corp. announces drill results at Charlotte property, Yukon

September 6, 2011

Investment Industry Regulatory Organization of Canada - Trading Halt - Ansell Capital Corp - ACP

September 1, 2011

Ansell capital corp. update on Charlotte and Discovery Creek properties, yukon

August 18, 2011

← Newer news releases · Older news releases →

Decks

The 5 newest of 12 decks. Every deck is listed under its year.